Clinical Trial Update: A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI) [Phase 2]

View source ↗

Summary

This document reports a Phase 2 open-label trial (PERELI) investigating the combination of pemigatinib and retifanlimab in advanced dedifferentiated liposarcoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dedifferentiated Liposarcoma

Drugs mentioned

• Pemigatinib (pemigatinib)
• Retifanlimab (retifanlimab)

Snippet

Sponsor: Lund University Hospital | Conditions: Dedifferentiated Liposarcoma | Phase 2 | Status: RECRUITING